Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors

Hepatology

Volumn 51, Issue 2, 2010, Pages 501-510

  Fracanzani, Anna Ludovica ^a   Piperno, Alberto ^b,c   Valenti, Luca ^a   Fraquelli, Mirella ^a   Coletti, Sabina ^b,c   Maraschi, Alessandra ^a   Consonni, Dario ^a,d   Coviello, Enzo ^e   Conte, Dario ^a   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Statistics and Epidemiology Unit ASL Bari   (Italy)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRON OVERLOAD; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL RATE;

FEMALE; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 75449106358     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23333     Document Type: Article

References (46)

1. Swinkels DW, Janssen MC, Bergmans J, Markx JJ. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 2006;52:950-968.
2. Arnold J, Sangwaiya A, Bhatkal B, Arnold A. Defective release of hepcidin not defective synthesis is the primary pathogenic mechanism in HFEhaemochromatosis. Med Hypotheses 2008;70:1197-2000.
3. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004;350:2383-2397.
4. Pietrangelo A. Non-HFE hemochromatosis. Semin Liver Dis 2005;25: 450-460.
5. Piperno A, Sampietro M, Pietrangelo A, Arosio C, Lupica L, Montosi G, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114:996-1002.
6. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;2;341:755-757.
7. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;15;103:2914-2919.
8. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-223.
9. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G->A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;19;359:211-218.
10. Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med 2008;358:221-230.
11. Allen KJ, Gurrin LC, Constantine CC, Delatycki MB, Nicoll AJ, McLaren CE, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;17;358:221-230.
12. Robson KJ, Merryweather-Clarke AT, Cadet E, Cadet E, Viprakasit V, Zaahl MG, et al. Recent advances in understanding haemochromatosis: a transition state. J Med Genet 2004;41:721-730.
13. Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008;111:4456-4462.
14. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. HEPATOLOGY 1992;15:655-659.
15. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. HEPATOLOGY 2008;48:991-1001.
16. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
17. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. HEPATOLOGY 1997;25:162-166.
18. Wheeler CJ, Kowdley KV. Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload. Compr Ther 2006;32:10-16.
19. Franchini M, Veneri D. Recent advances in hereditary hemochromatosis. Ann Hematol 2005;84:347-352.
20. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. Crit Rev Clin Lab Sci 2008; 45:451-484.
21. Altes A, Ruiz A, Martinez C. The relationship between iron overload and clinical characteristics in Spanish cohort of 100 C282Y homozygous hemochromatosis patients. Ann Hematol 2007;86:831-835.
22. Hover AR, McDonnell SM, Burke W. Changing the clinical management of hereditary hemochromatosis: translating screening and early case detection strategies into clinical practice. Arch Intern Med 2004;164:957-961.
23. Fowler C. Hereditary hemochromatosis: pathophysiology, diagnosis, and management. Crit Care Nurs Clin North Am 2008;20:191-201.
24. Jacobs EM, Verbeek AL, Kreeftenberg HG, van Deursen CT, Marx JJ, Stalenhoef AF, et al. Changing aspects of HFE-related hereditary haemochromatosis and endeavors to early diagnosis. Neth J Med 2007;65:419-424.
25. Tavill A. American Association for the Study of Liver Diseases Guidelines: diagnosis and management of hemochromatosis. HEPATOLOGY 2001;33: 1321-1328.
26. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
27. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003;138:627-633.
28. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-S37.
29. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, et al. High prevalence of the His63Asp HFE mutations in Italian patients with porphyria cutanea tarda. HEPATOLOGY 1998;27:181-184.
30. Girelli D, Bozzini C, Roetto A, Daraio F, Colombari R, Olivieri O, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002;122:1295-1302.
31. Pelucchi S, Mariani R, Salvioni A, Bonfadini S, Riva A, Bertola F, et al. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clin Genet 2008;73: 171-178.
32. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958;53:457-458.
33. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observations of each patients. II. Analysis and examples. Br J Cancer 1977;35:1-39.
34. Therneau TM, Grambsch PM. Modeling Survival Data Extending the Cox Model. New York: Springer; 2000.
35. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-624.
36. O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH. Declining prevalence of diabetes mellitus in hereditary hemochromatosis the results in earlier diagnosis. Diabetes Res Clin Pract 2008;81:316-320.
37. Powell EE, Ali A, Clouston AD, Dixon J, Lincoln DJ, Fletcher LM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005;129:1937-1943.
38. De Marco F, Liguori R, Giardina MG, D'Armiento M, Angelucci E, Lucariello A, et al. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med 2004; 42:17-24.
39. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 2000;26:163-168.
40. Hellerbrand C, Bosserhoff AK, Seegers S, Lingner G, Wrede C, Lock G, et al. Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol 2001;36:1211-1216.
41. D'Amelio R, Matricardi PM, Biselli R, Stroffolini T, Mele A, Spada E, et al. Changing epidemiology of hepatitis B in Italy: public health implications. Am J Epidemiol 1992;135:1012-1018.
42. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in northern Italy: a survey in the general population. J Clin Gastroenterol 2008;42: 527-532.
43. Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997;58:486-494.
44. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 2008;134:348-351.
45. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. HEPATOLOGY 2001;33:647-651.
46. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 2008;123:1883-1891.